New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
Therapeutic Area Partnerships is being held in Boston on November 28-30.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 19, 2015
07:23 EDTLLYTeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.
05:55 EDTARRYPiper sees 'transformative' two years for Array BioPharma
Piper Jaffray analyst Edward Tenthoff expects the next two years to be "transformative" for Array BioPharma (ARRY), with the company reporting pivotal data and likely gaining approval on wholly-owned MEK inhibitor binimetinib and BRAF inhibitor encorafenib. In addition, partner AstraZeneca (AZN) will report selumetinib data in uveal melanoma and file a new drug application this year resulting in royalty revenue to Array in 2016, the analyst tells investors today in a research note. Tenthoff reiterates an Overweight rating on the stock with a $15 price target.
June 18, 2015
09:35 EDTPFEActive equity options trading on open
Subscribe for More Information
June 17, 2015
12:02 EDTLLYEli Lilly reports LY2951742 meets primary endpoint in Phase 2b migraine study
Eli Lilly announced that its investigational medicine for prevention of migraine -- LY2951742, a CGRP neutralizing antibody -- met the primary endpoint in a Phase 2b study in episodic migraine. The randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of four different doses of LY2951742 given in a once-monthly, subcutaneous injection in more than 400 patients with episodic migraine. The primary objective was to assess whether at least one dose of LY2951742 was superior to placebo in the prevention of migraine headache. LY2951742 demonstrated a statistically significant reduction in migraine headache days and a safety and tolerability profile confirming the previous results seen in a Phase 2a study. In addition to the migraine program, Lilly has initiated two Phase 3 trials with LY2951742 in patients suffering from cluster headache. Based on the unmet medical need and significance of this disorder for patients, Lilly has been granted fast track designation from the U.S. FDA for cluster headache.
10:00 EDTPFE, LLYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
08:10 EDTLLYEli Lilly and Dana-Farber Cancer Institute enter research collaboration
Subscribe for More Information
08:02 EDTLLYEli Lilly partnering with Sarah Cannon Research Institute for oncology therapy
Eli Lilly and Sarah Cannon Research Institute announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
07:25 EDTPFE, LLYPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
07:21 EDTJNJGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
07:01 EDTAGENAgenus names C. Evan Ballantyne as CFO, effective immediately
Subscribe for More Information
05:31 EDTPFEPfizer initiated with an Overweight at Piper Jaffray
Target $45.
05:31 EDTLLYEli Lilly initiated with an Overweight at Piper Jaffray
Subscribe for More Information
June 16, 2015
08:36 EDTLLYEli Lilly price target raised to $100 from $87 at Jefferies
Jefferies raised its price target for Eli Lilly shares to $100 saying that while the market is "overly-obsessed" on the EXPEDITION-EXT abstract for Alzheimer's, the potential for cholesterol treatment evacetrapib should begin to be realized over the next 12 months. Jefferies keeps a Buy rating on Lilly.
June 15, 2015
11:15 EDTJNJIdera advances after JPMorgan starts coverage with $6 target
Subscribe for More Information
10:26 EDTLLYOptions with increasing implied volatility
Subscribe for More Information
09:19 EDTJNJ, LLYBiotech Industry Organization to hold a conference
BIO 2015 is being held in Philadelphia on June 15-18.
08:01 EDTPFEPfizer Consumer Healthcare to expand Caltrate, Centrum production in China
Pfizer Inc announced that it broke ground for a $95M consumer products production facility in Suzhou, China. The new site is near the company’s existing Suzhou site and will help increase production capacity to meet growing demand for Pfizer Consumer Healthcare’s brands in China and the Asia-Pacific region. The new facility will primarily produce Caltrate dietary supplements and Centrum multivitamins, and in the future will support production of additional products. There are also plans to eventually house a research and development facility on the site to help support innovation in the region.
07:19 EDTJNJGeron discloses orphan designation for its imetelstat for myelofibrosis
Subscribe for More Information
07:02 EDTSHPGArmaGen achieves clinical milestone in collaboration with Shire
ArmaGen announced that it achieved a clinical milestone in its worldwide licensing and collaboration agreement with Shire. The milestone was achieved in conjunction with dosing patients in its Phase 1 clinical trial of AGT-182, an investigational treatment of Hunter syndrome, and under terms of the agreement, the Company is entitled to a milestone payment from Shire. Also known as MPS II, Hunter syndrome is a rare, severe, progressive and life-limiting lysosomal storage disorder. The primary objective of the Phase 1 trial is to test the safety and determine a well-tolerated dose of AGT-182, an investigational enzyme replacement therapy, in adult patients with Hunter syndrome. ArmaGen plans to enroll 12 patients 18 years and older into the study. These patients will be treated for a total of eight weeks, with all enrolled patients receiving AGT-182.
07:01 EDTPFEVentana receives FDA approval for IHC companion diagnostic for Xalkori
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use